Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Medicinal cannabinoid oil is a full-spectrum, plant-derived cannabis oil formulation developed by **Zelira Therapeutics** (formerly Zelda Therapeutics). This botanical extract contains a standardized ratio of **delta-9-tetrahydrocannabinol (THC)** and **cannabidiol (CBD)**, along with other minor cannabinoids and terpenes found in the whole cannabis plant. The formulation targets the **endocannabinoid system**, specifically acting as an agonist at **CB1 and CB2 receptors** to modulate pain perception, reduce inflammation, and improve sleep and mood. It was primarily evaluated in a Phase I clinical trial in Australia (ACTRN12617001195303) for patients with chronic non-cancer pain to assess its safety, pharmacokinetics, and potential to reduce opioid dependence. The product is manufactured according to Good Manufacturing Practice (GMP) standards and is compliant with Australian Therapeutic Goods Administration (TGA) regulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on medicinal cannabinoid oil.